POWERED BY
- Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication (Revised)by Zacks Equity Research on October 21, 2021 at 6:49 am
Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.
- Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)by Zacks Equity Research on October 21, 2021 at 6:21 am
The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
- Old Second Bancorp (OSBC) Q3 Earnings and Revenues Surpass Estimatesby Zacks Equity Research on October 21, 2021 at 12:55 am
Old Second Bancorp (OSBC) delivered earnings and revenue surprises of 3.57% and 0.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- Great Southern Bancorp (GSBC) Q3 Earnings and Revenues Beat Estimatesby Zacks Equity Research on October 20, 2021 at 11:55 pm
Great Southern Bancorp (GSBC) delivered earnings and revenue surprises of 10.37% and 0.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- TriState Capital (TSC) Q3 Earnings Beat Estimatesby Zacks Equity Research on October 20, 2021 at 11:05 pm
TriState (TSC) delivered earnings and revenue surprises of 4.76% and -1.01%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
PORTFOLIO MANAGEMENT
